Lanma Medical was founded in December

2020 Settled in Suzhou Life Health Town

Focused on developing cellular immunotherapy products with TIL therapy as the core

The main direction is to genetically modify TIL cells to improve the efficacy of tumor treatment

Considered as the most competitive and industrialized "dark horse" technology for tackling solid tumors

and industrialization potential of the "dark horse" technology

In the first echelon of this field in China

In mid-2021, Blue Horse Medical completed an angel round of financing in the amount of tens of millions of RMB, and three months ago, received a Pre-A round of financing in the amount of tens of millions of USD, co-led by Boyuan Capital and IDG Capital, and followed by Sugo New Ventures.

The company's founding team has been working in the TIL field for many years, with long-term research experience in TIL laboratories of internationally renowned cancer research centers, mainly engaged in product development and process optimization of TILs therapeutics. They also have rich experience in the TIL industry and have participated in the completion of the corresponding product filing with the US FDA. From research to industry, the founding team has accumulated nearly 20 years of experience in product manufacturing, optimization and team management in the field of TIL therapeutics.

TIL (Tumorinfiltrating lymphocyte, TIL)

is the body's lymphocytes that invade into the tumor tissue

TIL (Tumorinfiltrating lymphocyte, TIL) is a group of cells that recognize, resist and attack tumors.

Compared to CAR-T cell therapy, TIL therapy is not only superior in safety, but also effective in attacking solid tumors. on August 12, 2021, a heavyweight study on TIL therapy caused a huge sensation and was published in the top journal Nature. The study showed that patients with clinically extremely difficult-to-treat advanced lung cancer that did not respond to PD-1 therapy were actually able to achieve long-term remission in some NSCLC patients who did not respond to PD-1 inhibitors after treatment with TIL as a cellular therapy. Even more exciting is that in this proof-of-concept clinical trial, two patients had complete tumor disappearance and sustained remission for more than a year and a half.

In terms of future product development direction, Blue Horse Medical will bring in more overseas scientists to join us to enrich the company's product pipeline. In the future, the company plans to conduct continuous exploration and research in multiple pathways and directions, such as genetically modifying TILs cells to improve the efficacy of TIL therapy, combining TIL therapy with other immunotherapies, targeted therapies or radiotherapy, and developing novel gene carriers to transport specific T cells to tumors, aiming to provide more choices and hope for patients.

High-end medical device industry cluster

It is one of the characteristic industrial innovation clusters that High-tech Zone is making every effort to build

In recent years

High-tech Zone has always adhered to the innovation-driven development strategy

Continuously increase innovation investment

Gathering innovative resources and promoting industrial development

The scale of the industry continues to expand

The total number of medical device and biomedical enterprises gathered is nearly 800, and the average annual growth rate of industrial output value is over 30%.

The innovation capacity has been significantly improved

We have introduced the platform of Suzhou Institute of Medical Technology of Chinese Academy of Sciences and Suzhou Institute of Medical Devices of Southeast University, set up the provincial medical device industry technology innovation center, and gathered more than 500 medical device and biomedical leading talents.

Continuous improvement of innovation ecology

A 10 billion yuan medical device industry mother fund and a 2 billion yuan science and innovation angel fund have been established; nearly 2 million square meters of professional carriers such as Jiangsu Medical Device Technology Industrial Park have been built; service platforms such as Suzhou Branch of Jiangsu Medical Device Testing Institute have been set up to provide all-round and full-coverage services for industrial development.

Future

Science and Technology Center of High-tech New Area

will focus on high-end medical and related fields

Introduce in vitro diagnostics, biomedical materials, implant interventional devices

High-quality enterprises in medical imaging equipment and treatment equipment, etc.

Help High-tech Zone build an internationally renowned and domestic first-class

High-end medical device industry innovation cluster